TABLE 3

Salivary APAP pharmacokinetics and urinary APAP metabolite excretion by UGT2B15 genotypes

Data are least squares means ± S.E.

	UGT2B151/1		UGT2B151/2		UGT2B152/2
	Basal	F&V	Basal	F&V	Basal	F&V
Salivary pharmacokinetics
n	16	16	33	33	17	17
C_max (mg/l)	15.9 ± 1.2	17.0 ± 1.3	15.4 ± 0.8^{^a}	17.3 ± 0.9^{^b}	17.8 ± 1.3	18.1 ± 1.3
Clearance (1/h)	10.2 ± 1.0	10.3 ± 1.0	9.3 ± 0.6	9.5 ± 0.6	12.1 ± 1.1	10.4 ± 1.0
AUC (mg · min/l)	5913 ± 504	5787 ± 493	6473 ± 377	6494 ± 373	5426 ± 449	5738 ± 482
t_1/2 (min)	307 ± 31^†	282 ± 28	270 ± 18^‡	290 ± 20	201 ± 19^{^a}^,^‡	268 ± 26^{^b}
Urinary APAP metabolite excretion
n	16	16	33	33	17	17
% of oral dose
%APAP	3.0 ± 0.2	2.9 ± 0.2	3.0 ± 0.1	3.2 ± 0.1	3.4 ± 0.2	3.5 ± 0.2
%APAPG	40.2 ± 1.6^†	40.9 ± 1.6^†	35.1 ± 1.1^‡	36.0 ± 1.1^‡	29.3 ± 1.5^§	30.4 ± 1.5^§
%APAPS^*	22.1 ± 1.6^{^a}^,^†	19.0 ± 1.5^{^b}^,^†	23.3 ± 1.1^{^a}^,^‡	21.6 ± 1.1^{^b}^,^‡	28.5 ± 1.5^{^a}^,^§	26.9 ± 1.5^{^b}^,^§
Metabolite ratios
APAPG ratio^{^c}^*	61.3 ± 1.8^{^a}^,^†	65.9 ± 1.8^{^b}^,^†	57.3 ± 1.2^{^a}^,^‡	59.4 ± 1.2^{^b}^,^‡	47.9 ± 1.7^{^a}^,^§	50.1 ± 1.8^{^b}^,^§
APAPG/APAP	13.9 ± 1.2^†	15.5 ± 1.3^†	12.2 ± 0.7^‡	11.7 ± 0.7^‡	8.9 ± 0.7^§	9.0 ± 0.7^§
APAPS/APAP^*	7.6 ± 0.7^{^a}	6.8 ± 0.6^{^b}	8.0 ± 0.5^{^a}	6.8 ± 0.4^{^b}	8.7 ± 0.7	8.0 ± 0.7

* Significant overall diet effect for UGT2B15 genotype (P < 0.05).
†,‡,§ <ths>Different superscript numbers represent significant genotype differences within diet (P < 0.05).
a,b Different superscript letters represent significant diet differences within a genotype (P < 0.05).
c APAPG/(APAP + APAPG + APAPS) × 100.